Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc.
Avidity Biosciences Inc. (RNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 7,625,000 | $225,090,000 | +2% | 3.51% |
| 2. | RA Capital Management Peter Kolchinsky | 6,300,408 | $185,988,044 | 3.11% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,145,881 | $63,346,407 | -23% | 0.12% |
| 4. | Casdin Capital Eli Casdin | 2,045,000 | $60,368,400 | 4.93% | |
| 5. | OrbiMed Advisors Samuel Isaly | 1,812,886 | $53,516,395 | +63% | 1.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 800,000 | $14,400,000.00 | 4,795,000 | 2021-08-04 | Filing | |
| $18.00 | 300,000 | $5,400,000.00 | 2,514,545 | 2020-06-16 | Filing | |
| $18.00 | 950,000 | $17,100,000.00 | 3,995,000 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.24 | 911 | $27,548.64 | 50,392 | 2025-06-17 | Filing | |
| $32.88 | 20,000 | $657,694.00 | 80,195 | 2025-06-11 | Filing | |
| $32.48 | 5,875 | $190,832.93 | 50,554 | 2025-06-02 | Filing | |
| $32.40 | 5,875 | $190,324.15 | 50,554 | 2025-05-01 | Filing | |
| $27.83 | 329 | $9,155.21 | 50,554 | 2025-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 41,389 | $1,175,448 | 0.19% | |
| 2. | 17,868 | $507,451 | 0% | |
| 3. | 7,700 | $218,680 | 0.08% | |
| 4. | 7,334 | $208,286 | 0.02% | |
| 5. | 1,705 | $48,422 | 0% |
News See All
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
10 Unstoppable Stocks That Could Double Your Money
Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
12 Best Multibagger Stocks to Buy Right Now
The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs.
7 Best Performing Long Term Stocks in 2024
After the latest 50 basis point rate cut by the Federal Reserve, the market has been performing well.
10 Best Performing Small-Cap Stocks in 2024
The recent Fed rate cut has made the market cautiously optimistic. Despite the unusual timing, historical data suggests a continued upward trend. Recently, we discussed the Dow's new all-time high.
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.
Is RNA A Good Stock To Buy According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September...
Billionaire Hedge Funds
